This protein datasheet indicates I need to use a cross-linking antibody, Catalog # MAB050, for biological activity. What is this antibody and is it really necessary?

The antibody is directed against a 6x histidine repeat and is recommended for use as a cross-linker of proteins with 6x his-tag. Crosslinking is often used for proteins that require receptor trimerization and can result greater biological activity. R&D Systems Quality Control tests the performance of these proteins in the presence of the cross-linking antibody. Therefore, it is necessary to use this antibody when trying to achieve the same level of specific activity described in the datasheet.

Is this protein provided in trimeric form or monomer form?

We do not define this protein as being exclusively a monomer, but we know that the protein is not fully associated into trimers because we need to use a cross-linking antibody for our in-house activity testing to cause multiple subunits of this protein to associate. This product has been shown to be biologically active in such testing when a cross-linking antibody is used. Therefore, we would expect for this protein to perform its expected biological function.

Recombinant Human TRANCE/RANK L/TNFSF11 Protein

Name: Recombinant Human TRANCE/RANK L/TNFSF11 Protein
Brand: R&D Systems
SKU: 390-TN
Rating: 5 (8 reviews)

Catalog # 390-TN | R&D Systems, Inc. a Bio-Techne Brand

(8)

Citations (39)

Product Datasheet / COA / SDS

New Version Available - 6449-TEC

A New rh TRANCE is Now Available! The new protein has no tag!

Catalog #

Availability

Size / Price

Qty

Setting the standard in quality research reagents

Key Product Details

Source:	NS0
Accession #:	AAC51762
Applications:	Bioactivity

View Full Technical Details for Recombinant Human TRANCE/RANK L/TNFSF11 Protein

Product Specifications for Recombinant Human TRANCE/RANK L/TNFSF11 Protein

Source

Mouse myeloma cell line, NS0-derived human TRANCE/TNFSF11/RANK L protein

MHHHHHHHHHH	GGGSGGGSGGGS	IEGR	Human TRANCE (Gly64-Asp245) Accession # AAC51762
N-terminus			C-terminus

Purity

>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal sequence Analysis

Met

Predicted Molecular Mass

23 kDa

SDS-PAGE

35 kDa, reducing conditions

Activity

Measured by its ability to induce osteoclast differentiation of RAW 264.7 mouse monocyte/macrophage cells. The ED₅₀ for this effect is 1.5-7.5 ng/mL in the presence of 2.5 µg/mL of a cross-linking antibody, Mouse Anti-polyHistidine Monoclonal Antibody (Catalog # MAB050).

Scientific Data Examples for Recombinant Human TRANCE/RANK L/TNFSF11 Protein

	Bioactivity of Human TRANCE / RANK L / TNFSF11 Protein Recombinant human TRANCE / RANK L / TNFSF11 (390-TN) induces osteoclast differentiation of the RAW264.7 mouse monocyte/macrophage cell line. The ED₅₀ for this effect is 1.5-7.5 ng/mL in the presence of 2.5 µg/mL of a cross-linking antibody, Mouse Anti-polyHistidine.

Formulation, Preparation and Storage

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

390-TN

Carrier

Formulation	Lyophilized from a 0.2 μm filtered solution in MOPS and NaCl with BSA as a carrier protein.
Reconstitution	Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

390-TN/CF

Carrier Free

Formulation	Lyophilized from a 0.2 μm filtered solution in MOPS and NaCl.
Reconstitution	Reconstitute at 100 μg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Background: TRANCE/TNFSF11/RANK L

RANK Ligand (receptor activator of NF-kappa B ligand [RANKL], also called TNF-related activation-induced cytokines (TRANCE), osteoprotegerin ligand [OPGL], and osteoclast differentiation factor [ODF]), is a member of the tumor necrosis factor (TNF) family. RANK Ligand was originally identified as an immediate early gene up‑regulated by T cell receptor stimulation. The human RANK Ligand cDNA encodes a type II transmembrane protein of 317 amino acids with a predicted cytoplasmic domain of 47 amino acids, a 21 amino acids transmembrane region, and an extracellular domain of 249 amino acids. The extracellular domain contains two potential N‑linked glycosylation sites. Mouse and human RANK Ligand share 85% amino acid identity. RANK Ligand is primarily expressed in T cells and T cell rich organs, such as thymus and lymph nodes. The multi-functions of RANK Ligand include induction of activation of the c-jun N‑terminal kinase, enhancement of T cell growth and dendritic cell function, induction of osteoclastogenesis, and lymph node organogenesis. RANK is the cell surface signaling receptor of RANK Ligand. RANK has been shown to undergo receptor clustering during signal transduction. Osteoprotegerin, a soluble member of the TNF receptor family which binds RANK Ligand, is a naturally occurring decoy receptor that counterbalances the effects of RANK Ligand.

Item	Value
References	Wong, B.R. et al. (1997) J. Biol. Chem. 272:25190. Anderson, D.M. et al. (1997) Nature 390:175. Nakagawa, N. et al. (1998) Biochem. Biophys. Res. Commun. 245:382. Kong, Y-Y. et al. (1999) Nature 397:315.
Long Name	TNF-related Activation-induced Cytokine
Entrez Gene IDs	8600 (Human); 21943 (Mouse); 117516 (Rat); 102137946 (Cynomolgus Monkey)
Alternate Names	CD254, CD254 antigen, ODF, OPGL, OPGLOPTB2, Osteoclast differentiation factor, Osteoprotegerin ligand, RANK L, RANKL, RANKLreceptor activator of nuclear factor kappa B ligand, Receptor activator of nuclear factor kappa-B ligand, TNF-related activation-induced cytokine, TNFSF11, TRANCE, TRANCEODFhRANKL2, sOdf, tumor necrosis factor (ligand) superfamily, member 11, tumor necrosis factor ligand superfamily member 11

Citations for Recombinant Human TRANCE/RANK L/TNFSF11 Protein (39)

Showing 1 - 10 of 39 citations Showing All

Filter By:

Search Title:

Citations are publications that use Bio-Techne products. Selected citations for Recombinant Human TRANCE/RANK L/TNFSF11 Protein include:

Species: Human
Sample Types: Whole Cells
Applications: Cell Culture

J Pape et al. (2022-12-24), RANKL neutralisation prevents osteoclast activation in a human in vitro ameloblastoma-bone model Journal of tissue engineering, 2022-113(0):2041731422114.
PMID: 36582941
Species: Rat
Sample Types: Whole Cells
Applications: Bioassay

D Ding et al. (2022-07-28), Zoledronic acid generates a spatiotemporal effect to attenuate osteoarthritis by inhibiting potential Wnt5a-associated abnormal subchondral bone resorption PLoS ONE, 2022-017(7):e0271485.
PMID: 35900969
Species: Mouse
Sample Types: Whole Cells
Applications: Bioassay

H Guo et al. (2021-12-16), Metformin attenuates osteoclast-mediated abnormal subchondral bone remodeling and alleviates osteoarthritis via AMPK/NF-kappaB/ERK signaling pathway PLoS ONE, 2021-116(12):e0261127.
PMID: 34914744
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

J Xue et al. (2020-09-21), CD14+CD16- monocytes are the main precursors of osteoclasts in rheumatoid arthritis via expressing Tyro3TK Arthritis Research Therapy, 2020-09-21;22(1):221.
PMID: 32958023
Species: Human
Sample Types: Whole Cells
Applications: Cell Culture

JS Brunner et al. (2020-01-22), Environmental arginine controls multinuclear giant cell metabolism and formation Nat Commun, 2020-011(1):431.
PMID: 31969567
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

KA Lee et al. (2019-12-12), Promotion of osteoclastogenesis by IL-26 in rheumatoid arthritis Arthritis Res. Ther., 2019-121(1):283.
PMID: 31831038
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

I Zoi et al. (2019-12-03), Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas Breast Cancer Res., 2019-121(1):132.
PMID: 31796128
Species: Human
Sample Types: Whole Cells
Applications: Cell Culture

K Li et al. (2019-11-06), MiRNA-483-5p is involved in the pathogenesis of osteoporosis by promoting osteoclast differentiation Mol. Cell. Probes, 2019-10(0):101479.
PMID: 31706013
Species: Human
Sample Types: Whole Cells
Applications: Cell Culture

N Ogasawara et al. (2019-10-22), Role of RANK-L as a potential inducer of ILC2-mediated type 2 inflammation in chronic rhinosinusitis with nasal polyps Mucosal Immunol, 2019-113(1):86-95.
PMID: 31641233
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

IJ Yeh et al. (2019-09-28), 6-Shogaol Suppresses 2-Amino-1-Methyl-6-Phenylimidazo [4,5-b] Pyridine (PhIP)-Induced Human 786-O Renal Cell Carcinoma Osteoclastogenic Activity and Metastatic Potential Nutrients, 2019-011(10).
PMID: 31569368
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

FL Collins et al. (2019-07-12), Oestrogen-deficiency induces bone loss by modulating CD14+ monocyte and CD4+ T cell DR3 expression and serum TL1A levels BMC Musculoskelet Disord, 2019-020(1):326.
PMID: 31299941
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

H Löfvall et al. (2019-02-28), GPDPLQ1237-A Type II Collagen Neo-Epitope Biomarker of Osteoclast- and Inflammation-Derived Cartilage Degradation in vitro Sci Rep, 2019-09(1):3050.
PMID: 30816326
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

AMJ Møller et al. (2018-08-29), Septins are critical regulators of osteoclastic bone resorption Sci Rep, 2018-08(1):13016.
PMID: 30158637
Species: Human
Sample Types: Whole Cells
Applications: Cell Culture

CF Kjelgaard- et al. (2018-07-24), Translational Biomarkers and Ex Vivo Models of Joint Tissues as a Tool for Drug Development in Rheumatoid Arthritis Arthritis rheumatology (Hoboken, N.J.), 2018-07-24;0(0).
PMID: 29669391
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

C Davenport et al. (2018-04-10), RANKL Inhibits the Production of Osteoprotegerin from Smooth Muscle Cells under Basal Conditions and following Exposure to Cyclic Strain J. Vasc. Res., 2018-055(2):111-123.
PMID: 29635231
Species: Human
Sample Types: Recombinant Protein
Applications: Surface Plasmon Resonance (SPR

AW Clarke et al. (2018-03-05), An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease MAbs, 2018-00(0):1-43.
PMID: 29436901
Species: Equine
Sample Types: Whole Cells
Applications: Bioassay

H Hussein et al. (2017-12-18), Cathepsin K Localizes to Equine Boneand Inhibits Bone Marrow Stem and Progenitor Cells Differentiation J Stem Cells Regen Med, 2017-113(2):45-53.
PMID: 29391749
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

A Sucur et al. (2017-06-15), Chemokine signals are crucial for enhanced homing and differentiation of circulating osteoclast progenitor cells Arthritis Res. Ther., 2017-019(1):142.
PMID: 28619088
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

B Lu et al. (2017-05-19), A FKBP5 mutation is associated with Paget's disease of bone and enhances osteoclastogenesis Exp. Mol. Med., 2017-049(5):e336.
PMID: 28524179
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

G Chinetti-G et al. (2017-04-24), Human Alternative Macrophages Populate Calcified Areas of Atherosclerotic Lesions and Display Impaired RANKL-Induced Osteoclastic Bone Resorption Activity Circ. Res., 2017-00(0).
PMID: 28438779
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

A Kamalakar et al. (2017-04-19), PTHrP(12-48) Modulates the Bone Marrow Microenvironment and Suppresses Human Osteoclast Differentiation and Lifespan J. Bone Miner. Res., 2017-00(0).
PMID: 28370412
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

Giulia Bellini (2016-12-02), PKC?II-mediated cross-talk of TRPV1/CB2 modulates the glucocorticoid-induced osteoclast overactivity Pharmacol. Res, 2016-10(0).
PMID: 27919827
Sample Types: Protein
Applications: Bioassay

Justin R Savage (2016-06-16), A Modified Glycosaminoglycan, GM-0111, Inhibits Molecular Signaling Involved in Periodontitis PLoS ONE, 2016-011(6):e0157310.
PMID: 27308827
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

Kasonga A et al. (2015-04-13), Arachidonic acid and docosahexaenoic acid suppress osteoclast formation and activity in human CD14+ monocytes, in vitro. PLoS ONE, 2015-010(4):e0125145.
PMID: 25867515
Species: Mouse
Sample Types: Whole Cells
Applications: Bioassay

Zhu K et al. (2015-02-03), Impaired bone homeostasis in amyotrophic lateral sclerosis mice with muscle atrophy. J Biol Chem, 2015-0290(13):8081-94.
PMID: 25648889
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

Kalbasi Anaraki P et al. (2015-02-01), Urokinase receptor mediates osteoclastogenesis via M-CSF release from osteoblasts and the c-Fms/PI3K/Akt/NF-kappaB pathway in osteoclasts. J Bone Miner Res, 2015-030(2):379-88.
PMID: 25196912
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

Alshbool F et al. (2014-12-05), Differential expression of claudin family members during osteoblast and osteoclast differentiation: Cldn-1 is a novel positive regulator of osteoblastogenesis. PLoS ONE, 2014-19(12):e114357.
PMID: 25479235
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

Zheng Y et al. (2014-09-01), Direct crosstalk between cancer and osteoblast lineage cells fuels metastatic growth in bone via auto-amplification of IL-6 and RANKL signaling pathways. J Bone Miner Res, 2014-029(9):1938-49.
PMID: 24676805
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

Yeon J et al. (2014-02-21), Anti-osteoclastogenic activity of praeruptorin A via inhibition of p38/Akt-c-Fos-NFATc1 signaling and PLCgamma-independent Ca2+ oscillation. PLoS ONE, 2014-09(2):e88974.
PMID: 24586466
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

Chen C et al. (2014-02-01), MiR-503 regulates osteoclastogenesis via targeting RANK. J Bone Miner Res, 2014-029(2):338-47.
PMID: 23821519
Species: Human

Applications: Bioassay

Liu Z et al. (2013-12-10), Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression. PLoS ONE, 2013-18(12):e82453.
PMID: 24340030
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

He W et al. (2013-05-16), Adenosine regulates bone metabolism via A1, A2A, and A2B receptors in bone marrow cells from normal humans and patients with multiple myeloma. FASEB J, 2013-027(9):3446-54.
PMID: 23682121
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

Wilson TR et al. (2012-07-26), Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature, 2012-0487(7408):505-9.
PMID: 22763448
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

Soe K et al. (2010-10-01), Glucocorticoids maintain human osteoclasts in the active mode of their resorption cycle. J. Bone Miner. Res., 2010-125(10):2184-92.
PMID: 20499345
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

Boissy P et al. (2008-04-18), Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions. Leuk. Res., 2008-032(11):1661-8.
PMID: 18394701
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

Colucci S et al. (2007-05-01), Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFalpha, and IL-7 in an in vitro model derived from human psoriatic arthritis. J. Pathol., 2007-0212(1):47-55.
PMID: 17370327
Species: Mouse
Sample Types: Whole Cells
Applications: Bioassay

Tang CH et al. (2006-11-10), Attenuation of bone mass and increase of osteoclast formation in decoy receptor 3 transgenic mice. J. Biol. Chem., 2006-1282(4):2346-54.
PMID: 17099218
Species: Mouse
Sample Types: Whole Cells
Applications: Bioassay

Kawai T et al. (2006-09-01), B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am. J. Pathol., 2006-0169(3):987-98.
PMID: 16936272
Sample Types: N/A
Applications: ELISA (Standard)

Grimaud E et al. (2003-11-01), Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am. J. Pathol., 2003-1163(5):2021-31.
PMID: 14578201

There are no citations that match your criteria.

Showing 1 - 10 of 39 citations Showing All

Customer Reviews for Recombinant Human TRANCE/RANK L/TNFSF11 Protein (8)

4.8 out of 5

8 customer ratings

5 stars

75%

4 stars

25%

3 stars

2 stars

1 star

Customer Images

Showing 1 - 5 of 8 reviews Showing All

Filter By:

Recombinant Human TRANCE/RANK L/TNFSF11 Protein

Name: Zijun Zhang

Application: In vitro bioactivity in cell culture

Verified Customer | Posted 05/17/2022
Recombinant Human TRANCE/RANK L/TNFSF11 Protein

Name: Anonymous

Application: In vitro bioactivity in cell culture

Reason for Rating: Steady quality! 60 ng/ml RANKL can induce monocyte to osteoclast very well.

Verified Customer | Posted 12/31/2021
Recombinant Human TRANCE/RANK L/TNFSF11 Protein

Name: Anonymous

Application: In vitro bioactivity in cell culture

Reason for Rating: 50ng/ml RANKL is good for induce the human monocyte to osteoclast.

Verified Customer | Posted 03/20/2021
Recombinant Human TRANCE/RANK L/TNFSF11 Protein

Name: Anonymous

Application: In vitro bioactivity in cell culture

Reason for Rating: 50ng/ml RANKL, 25ng/ml M-CSF in a-MEM works well for human osteoclasts.

Verified Customer | Posted 01/18/2021
Name: Vaishali Sarode

Application: CellProlif

Verified Customer | Posted 02/06/2019
Recombinant Human TRANCE/RANK L/TNFSF11 Protein

Name: Anonymous

Application: Characterization by MS

Verified Customer | Posted 01/05/2018
Name: Abby Sukarto

Verified Customer | Posted 05/16/2017
Recombinant Human TRANCE/RANK L/TNFSF11 Protein

Name: preety panwar

Application: CellProlif

Verified Customer | Posted 05/18/2016

There are no reviews that match your criteria.

Showing 1 - 5 of 8 reviews Showing All

FAQs for Recombinant Human TRANCE/RANK L/TNFSF11 Protein

This protein datasheet indicates I need to use a cross-linking antibody, Catalog # MAB050, for biological activity. What is this antibody and is it really necessary?

The antibody is directed against a 6x histidine repeat and is recommended for use as a cross-linker of proteins with 6x his-tag. Crosslinking is often used for proteins that require receptor trimerization and can result greater biological activity. R&D Systems Quality Control tests the performance of these proteins in the presence of the cross-linking antibody. Therefore, it is necessary to use this antibody when trying to achieve the same level of specific activity described in the datasheet.
Is this protein provided in trimeric form or monomer form?

We do not define this protein as being exclusively a monomer, but we know that the protein is not fully associated into trimers because we need to use a cross-linking antibody for our in-house activity testing to cause multiple subunits of this protein to associate. This product has been shown to be biologically active in such testing when a cross-linking antibody is used. Therefore, we would expect for this protein to perform its expected biological function.
What are the differences between the Recombinant Human TRANCE/RANK L/TNFSF11 Protein (Catalog # 390-TN) and the Recombinant Human TRANCE/RANK L/TNFSF11 (Catalog # 6449-TEC)?

6449-TEC is the truncated version of 390-TN, and it contains a 10-His tag in the N-terminus. The bioactivity of 390-TN and 6449-TEC are measured in the same assay described in the datasheet, "Measured by its ability to induce osteoclast differentiation of RAW 264.7 mouse monocyte/macrophage cells." However, 390-TN utilizes a cross-linking antibody, MAB050, as it requires receptor trimerization which results in higher bioactivity. The ED50 for 390-TN is 1.5-7.5 ng/mL in the presence of MAB050, while the ED50 for 6449-TEC is 2-12 ng/mL.

Recombinant Human TRANCE/RANK L/TNFSF11 Protein

Catalog # 390-TN | R&D Systems, Inc. a Bio-Techne Brand

Key Product Details

Customers also Viewed

Product Specifications for Recombinant Human TRANCE/RANK L/TNFSF11 Protein

Scientific Data Examples for Recombinant Human TRANCE/RANK L/TNFSF11 Protein

Formulation, Preparation and Storage

Carrier Free

390-TN

Carrier

390-TN/CF

Carrier Free

Reconstitution Calculator

Background: TRANCE/TNFSF11/RANK L

Citations for Recombinant Human TRANCE/RANK L/TNFSF11 Protein (39)

Customer Reviews for Recombinant Human TRANCE/RANK L/TNFSF11 Protein (8)

Customer Images

Recombinant Human TRANCE/RANK L/TNFSF11 Protein

Recombinant Human TRANCE/RANK L/TNFSF11 Protein

Recombinant Human TRANCE/RANK L/TNFSF11 Protein

Recombinant Human TRANCE/RANK L/TNFSF11 Protein

Recombinant Human TRANCE/RANK L/TNFSF11 Protein

Recombinant Human TRANCE/RANK L/TNFSF11 Protein

FAQs for Recombinant Human TRANCE/RANK L/TNFSF11 Protein

Product Documents for Recombinant Human TRANCE/RANK L/TNFSF11 Protein

Product Datasheets

COA

Certificate of Analysis

SDS

Bio-Techne Brands

Stay Connected